SUBSCRIBE
SUBSCRIBE

OnCusp Therapeutics

NEWS
NextGen
BioSpace’s NextGen Class of 2025 Leans Into Biopharma’s Hottest Trends
From ADCs and radiopharmaceuticals to cell and gene therapies, eager young startups are betting on advances in biopharma’s most competitive therapeutic spaces—and attracting dollars from Big Pharma.
January 7, 2025
 · 
4 min read
 · 
Heather McKenzie
Pictured: Jar of money / Adobe Stock, juliasudnits
ADC-Focused OnCusp Therapeutics Emerges with $100M Series A Raise
Targeting the red hot antibody-drug conjugate market, OnCusp Therapeutics is coming out of the gate with $100 million from investors such as Novo Holdings and OrbiMed.
January 5, 2024
 · 
2 min read
 · 
Tyler Patchen
IN THE PRESS
Drug Development
OnCusp Therapeutics Announces First Patient Dosed in Phase 1 Trial of CUSP06 in Patients with Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
March 6, 2024
 · 
3 min read
Pharm Country
OnCusp Therapeutics Raises Oversubscribed $100 Million Series A Financing to Advance Portfolio of Assets for Cancer Patients
January 4, 2024
 · 
4 min read
Drug Development
OnCusp Therapeutics Receives FDA Clearance for the Phase 1 Clinical Trial of CUSP06, Targeting Ovarian Cancer and Other Advanced Solid Tumors
August 15, 2023
 · 
2 min read
OnCusp Therapeutics Showcases Potent Anti-Tumor Activity of its CDH6 ADC at AACR Annual Meeting 2023
April 11, 2023
 · 
2 min read
Business
OnCusp Therapeutics and Multitude Therapeutics Enter into an Ex-China Licensing Agreement for a Potentially Highly Differentiated CDH6-Targeting Antibody Drug Conjugate
June 8, 2022
 · 
4 min read
Business
OnCusp Therapeutics Commences Operations to Advance Innovative Oncology Therapies
June 29, 2021
 · 
6 min read
AWARDS
  • NextGen Class of 2025
JOBS